Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
191 hedge funds and large institutions have $2.25B invested in Global Blood Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 81 increasing their positions, 57 reducing their positions, and 41 closing their positions.
433% more call options, than puts
Call options by funds: $59.8M | Put options by funds: $11.2M
42% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 57
11% less funds holding
Funds holding: 214 → 191 (-23)
17% less capital invested
Capital invested by funds: $2.7B → $2.25B (-$449M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
54% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$61.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.5M |
| 4 |
CC
Casdin Capital
New York
|
+$16M |
| 5 |
Morgan Stanley
New York
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$57.2M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$54M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$42.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$35.4M |
| 5 |
JP Morgan Chase
New York
|
-$27M |
GBT Hedge Fund Activity: Q2 2021 in Review
191 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2021, worth a combined $2.25B — down 17% from $2.7B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of GBT and 19 opened new positions — a net loss of 22 holders — while 57 trimmed existing stakes and 81 added.
The largest buyer was BlackRock, adding an estimated $61.6M. The largest seller was Fidelity Investments, cutting an estimated $57.2M.
- 191 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2021, down from 214 in Q1 2021.
- Funds reported $2.25B of Global Blood Therapeutics, Inc. stock for Q2 2021, down 17% quarter-over-quarter.
- 19 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2021 and 41 closed out, a net change of -22 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2021 was BlackRock, an estimated $61.6M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2021 was Fidelity Investments, an estimated $57.2M sold.
Based on aggregated 13F filings for Q2 2021.